Value proposition

Unique know-how to discover and engineer novel antibody therapeutics in immunology & inflammation (I&I) and neurology.

Mabylon AG, a private Swiss biotech company, is leading innovation in antibody-based treatments for severe allergies, inflammation, and neurological disorders. Our B-cell screening platform rapidly identifies natural human antibodies with high specificity and therapeutic potential. MY006, our first-in-class multispecific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.